Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia-Reference-Cited by-同舟云学术

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

Published:2017-04-07 Issue:15 Volume:123 Page:2867-2874
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Battipaglia Giorgia¹²^ORCID,Ruggeri Annalisa¹,Massoud Radwan³^ORCID,El Cheikh Jean³,Jestin Matthieu¹,Antar Ahmad³,Ahmed Syed Osman⁴,Rasheed Walid⁴,Shaheen Marwan⁴,Belhocine Ramdane¹,Brissot Eolia¹,Dulery Remy¹,Eder Sandra¹,Giannotti Federica¹,Isnard Francoise¹,Lapusan Simona¹,Rubio Marie-Therese¹,Vekhoff Anne¹,Aljurf Mahmoud⁴,Legrand Ollivier¹,Mohty Mohamad¹⁵⁶,Bazarbachi Ali³⁷

Affiliation:

1. Hematology and Cellular Therapy Service, Saint Antoine Hospital, AP-HP; Paris France

2. Department of Hematology and Marrow Transplantation; Federico II University; Naples Italy

3. Bone Marrow Transplantation Program; Department of Internal Medicine, American Universit6y of Beirut Medical Center; Beirut Lebanon

4. Adult Hematology/HSCT Section, Oncology Center, King Faisal Specialist Hospital and Research Centre; Riyadh Saudi Arabia

5. Hospital Saint-Antoine, Paris University UPMC; Paris France

6. INSERM; Paris France

7. Department of Cell Biology; Anatomy and Physiological Sciences, American University of Beirut; Beirut Lebanon

Funder

Association for Training, Education and Research in Hematology, Immunology and Transplantation (ATERHIT; Nantes, France)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Acute myeloid leukemia. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm;Frohling;Blood,2002

2. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?;Levis;Hematology Am Soc Hematol Educ Program,2013

3. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis;Brunet;J Clin Oncol,2012

4. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412;Stone;Blood,2005

5. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status;Cortes;J Clin Oncol,2013

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia;Annals of Hematology;2023-11-17

2. Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study;Signal Transduction and Targeted Therapy;2023-09-14

3. Donor lymphocyte infusion in Acute Myeloid Leukemia;Best Practice & Research Clinical Haematology;2023-09

4. Recent advances in allogeneic transplantation for acute myeloid leukemia;Current Opinion in Oncology;2023-08-30

5. Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party;Clinical Cancer Research;2023-08-21